Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection

By Chunyan Wang, Wentao Li, D. Drabek, Nisreen M. A. Okba, R. van Haperen, A. Osterhaus, F. V. van Kuppeveld, B. Haagmans, Frank G. Grosveld, B. Bosch. 2020

53 citations recorded by the source corpus.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Subfields: Immunology

Citations in the corpus

• Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, neutral): “…domain (RBD) in complex with ACE2 defined key residues involved in recognition and guide surveillance studies aiming to detect the emergence of mutants with altered binding affinity for ACE2 or distinct antigenicity (Lan et al., 2020; Shang et al., 2020; Wang et al., 2020b; Yan et al., 2020).”
• Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients (2020, unknown): “We used a standard curve of the anti-SARS-CoV-2 monoclonal, CR3022 (24), to calculate the concentration of anti-RBD IgG, IgA, and IgM expressed in μg/mL. Note : For the DBS and plasma comparisons the starting concentration was 1:200.”